A Trial to Investigate Long Term Efficacy and Safety of Lonapegsomatropin in Adults With Growth Hormone Deficiency
Status:
Recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 open-label multicenter extension study designed to evaluate the long-term
safety and efficacy of Lonapegsomatropin administered once-weekly. The study participants are
adults (males and females) with confirmed growth hormone deficiency (GHD) having completed
the treatment period in study TCH-306 (foresiGHt).